concept

RB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2519Connections

26Hypotheses

0Analyses

50Outgoing

50Incoming

2Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	RB
Linked Hypotheses	5 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    RB["RB"]
    style RB fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    RB -->|"interacts"| Als["Als"]
    RB -.->|"inhibits"| Atherosclerosis["Atherosclerosis"]
    RB -->|"activates"| Dementia["Dementia"]
    RB -->|"activates"| Alzheimer["Alzheimer"]
    RB -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    RB -->|"interacts"| Parkinson["Parkinson"]
    MTOR([MTOR]) -.->|"inhibits"| RB
    AMPK([AMPK]) -->|"interacts"| RB
    ABCA1([ABCA1]) -->|"interacts"| RB
    P2RY12([P2RY12]) -.->|"inhibits"| RB
    ABCG1([ABCG1]) -->|"interacts"| RB
    ALS([ALS]) -->|"interacts"| RB
    MAO([MAO]) -.->|"inhibits"| RB
    ULK1([ULK1]) -->|"interacts"| RB
    ATP([ATP]) -->|"interacts"| RB
    ACTB([ACTB]) -->|"interacts"| RB

Outgoing (446)

Target	Relation	Type	Str
Ferroptosis	regulates	disease	0.60
Huntington	regulates	disease	0.60
Als	biomarker_for	disease	0.60
Dementia	regulates	disease	0.60
Dementia	therapeutic_target	disease	0.60
Prion Disease	regulates	disease	0.60
Atherosclerosis	associated_with	disease	0.60
Atherosclerosis	inhibits	disease	0.60
Als	causes	disease	0.60
Alzheimer	causes	disease	0.60
Cerebral Amyloid Angiopathy	activates	disease	0.60
Epilepsy	inhibits	disease	0.60
Anxiety	therapeutic_target	disease	0.60
Alzheimer	activates	disease	0.60
Alzheimer	regulates	disease	0.60
Als	protects_against	disease	0.60
Frontotemporal Dementia	interacts_with	disease	0.60
Parkinson	interacts_with	disease	0.60
Alzheimer	interacts_with	disease	0.60
Ferroptosis	biomarker_for	disease	0.60
Dementia	causes	disease	0.60
Vascular Dementia	causes	disease	0.60
Frontotemporal Dementia	activates	disease	0.60
Neurodegeneration	activates	disease	0.60
Als	activates	disease	0.60
Aging	therapeutic_target	disease	0.60
Dementia	activates	disease	0.60
Spinal Muscular Atrophy	regulates	disease	0.60
Fibrosis	interacts_with	disease	0.60
Cancer	interacts_with	disease	0.60
Als	interacts_with	disease	0.60
Ptsd	inhibits	disease	0.60
Dementia	interacts_with	disease	0.60
Neurodegeneration	biomarker_for	disease	0.60
Multiple Sclerosis	therapeutic_target	disease	0.60
Neuroinflammation	causes	disease	0.60
Amyotrophic Lateral Sclerosis	therapeutic_target	disease	0.60
Parkinson	therapeutic_target	disease	0.60
Neurodegeneration	causes	disease	0.60
Alzheimer	therapeutic_target	disease	0.60
Spinal Muscular Atrophy	interacts_with	disease	0.60
Aging	interacts_with	disease	0.60
Neurodegeneration	interacts_with	disease	0.60
Ischemia	causes	disease	0.60
Ferroptosis	causes	disease	0.60
Obesity	regulates	disease	0.60
Diabetes	regulates	disease	0.60
Atherosclerosis	regulates	disease	0.60
Neuroinflammation	regulates	disease	0.60
Tauopathy	therapeutic_target	disease	0.60

Incoming (2073)

Source	Relation	Type	Str
NTN3	interacts_with	gene	0.60
TAU	interacts_with	gene	0.60
VPS35	therapeutic_target	gene	0.60
PINK1	therapeutic_target	gene	0.60
PARK7	therapeutic_target	gene	0.60
CXCL10	associated_with	gene	0.60
CXCR3	associated_with	gene	0.60
HSP90	activates	gene	0.60
TLR2	activates	gene	0.60
AQP4	activates	gene	0.60
CNTNAP4	activates	gene	0.60
C1Q	causes	gene	0.60
IL6R	inhibits	gene	0.60
IL6	inhibits	gene	0.60
TREM2	inhibits	gene	0.60
IDO1	associated_with	gene	0.60
SLC7A11	expressed_in	gene	0.60
ICAM1	activates	gene	0.60
OCLN	activates	gene	0.60
TNFRSF1A	activates	gene	0.60
CRY1	activates	gene	0.60
IBA1	activates	gene	0.60
CLDN1	inhibits	gene	0.60
STAT6	inhibits	gene	0.60
NRF2	inhibits	gene	0.60
GLI1	activates	gene	0.60
ATG7	activates	gene	0.60
BNIP3	activates	gene	0.60
BCL2	activates	gene	0.60
PIEZO1	regulates	gene	0.60
EGF	activates	gene	0.60
NRF2	activates	gene	0.60
KEAP1	activates	gene	0.60
NRF2	regulates	gene	0.60
PKC	activates	gene	0.60
BACH1	activates	gene	0.60
FYN	activates	gene	0.60
UBIQUITIN	regulates	gene	0.60
CRH	regulates	gene	0.60
CRH	associated_with	gene	0.60
GAIN	therapeutic_target	gene	0.60
MTOR	therapeutic_target	gene	0.60
TP53	activates	gene	0.60
GAIN	associated_with	gene	0.60
NPTX2	regulates	gene	0.60
MTCL1	inhibits	gene	0.60
UBIQUITIN	inhibits	gene	0.60
UBQLN2	associated_with	gene	0.60
MMP9	inhibits	gene	0.60
JUN	expressed_in	gene	0.60

Targeting Hypotheses (26)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary
Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ	0.738	neuroinflammation	How do B cells mechanistically orchestra
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Ne	0.670	neurodegeneration	What are the specific molecular mechanis

Vascular mural cell degeneration precedes and exacerbates pa	0.661	alzheimers	SEA-AD Single-Cell Analysis: Cell-Type V
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Sex-Specific Microglial States in Amyloi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Genetic Aging Landscape Variants and Epi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Causal Sequence of TDP-43 Nuclear Cleara
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	CCL2-CCR2 Axis at NMJ: Mechanism of Sele
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Non-Neuronal Transcriptional Changes Pre
Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met	0.597	neuroinflammation	What molecular mechanisms determine whet
Parthenolide perturbs adenosine transport or metabolism upst	0.506	neuropharmacology	How does parthenolide specifically modul
REV-ERB Agonist Microglial Deactivation	0.455	chronobiology	Can circadian interventions reverse micr
Phosphatidylserine Decarboxylase (PISD) Restoration to Corre	0.342	lipidomics	Lipid metabolism dysregulation in Alzhei
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacolog	0.308	metabolomics	Metabolomic signatures of neurodegenerat
Compensatory RBP Expression Therapy	0.000	-	RNA binding protein dysregulation across
Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Proteostasis Network Activation for RBPs	0.000	-	RNA binding protein dysregulation across

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
IL-10 deficiency and VLC ceramide accumulation in inflammatory bowel d	validation	inflammatory bowel disease	0.900	0.00	IL-10 knockout mice	proposed	N/A
Irisin effects on angiogenesis in human endothelial cells	exploratory	bone fracture	0.900	0.00	human umbilical vein endotheli	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990]	Keller A	Annual review of physiology	2026
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811]	Wang Y, Zhang Z, Cao L, Huang S, Huang X	J Ethnopharmacol	2026
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710]	Yang X, Xiao JH, Li X, Liu RM, Yuan Q	J Ethnopharmacol	2026
Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296]	Maier AD, Laurentiussen CO, Michaelsen S	Acta Neuropathol Commun	2026
Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797]	Prabhudesai S, Thirugnanam K, Song X, Ya	Life Sci Alliance	2026
Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860]	Li J, Li A, Ye C, Zhang L, Jiang M et al	Mol Neurodegener	2026
FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210]	Sun F, Zhao Y, Do J, Cheng P, Li E et al	Nat Commun	2026
Loss of Pericyte Exacerbates Alzheimer's Disease-Associated Retinal Pathology. [PMID:41814129]	Hai-Chao C, Fu-Lin G, Jia-Xin C, Yi-Shu	Clinical & experimental ophtha	2026

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning RB in their description or question text

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro